Les microARN dans le cancer du foie

Gougelet, Angélique; Colnot, Sabine

doi:10.1051/medsci/20132910013

Cited by 10 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They could be of diagnostic significance for many liver diseases; however, current literature has been focused on tumors in the liver [25], [26], [27]. Our study revealed that serum miR-122-5p, miR-1290, miR-27b-3p, and miR-192-5p were potential circulating markers for diagnosing NAFLD.…”

Section: Discussionmentioning

confidence: 68%

A Pilot Study of Serum MicroRNAs Panel as Potential Biomarkers for Diagnosis of Nonalcoholic Fatty Liver Disease

et al. 2014

View full text Add to dashboard Cite

BackgroundThe invasive nature of liver biopsy makes the histopathological diagnosis of non-alcoholic fatty liver disease (NAFLD) difficult and its diagnostic performance unsatisfactory. The present study aimed to identify a serum microRNA (miRNA) expression profile that could serve as a novel diagnostic biomarker for NAFLD.MethodsSerum miRNA expression was investigated using three cohorts comprising 465 participants (healthy controls and NAFLD patients) recruited between August 2010 and June 2013. miRNA expression was initially screened by Illumina sequencing using serum samples pooled from 20 patients and 20 controls. Quantitative reverse transcriptase polymerase chain reaction assay was then used to evaluate the expression of selected miRNAs. A logistic regression model was constructed using a training cohort (n = 242) and validated using another cohort (n = 183). The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy.ResultsWe identified an miRNA panel (hsa-miR-122-5p, hsa-miR-1290, hsa-miR-27b-3p, and hsa-miR-192-5p) with a high diagnostic accuracy for NAFLD. The satisfactory diagnostic performance of the miRNA panel remained regardless of the NAFLD activity score (NAS) status. There was significant difference between the AUC values of the miRNA panel and those of ALT (AUC = 0.786, 95% CI = 0.717–0.855; P = 0.142) and FIB-4 (AUC = 0.795, 95% CI = 0.730–0.860; sensitivity = 69.9%, specificity = 83.7%.ConclusionWe identified a serum microRNA panel with considerable clinical value in NAFLD diagnosis. The results indicate that the miRNA panel is a more sensitive and specific biomarker for NAFLD than ALT and FIB-4.

show abstract

Section: Discussionmentioning

confidence: 68%

A Pilot Study of Serum MicroRNAs Panel as Potential Biomarkers for Diagnosis of Nonalcoholic Fatty Liver Disease

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Deregulation of miRNA expression may be a key pathogenic factor in many liver diseases, including viral hepatitis, hepatocellular carcinoma (HCC), metabolic and acute liver diseases. miRNA expression profiles are altered in many hepatic diseases compared to that of healthy subject [28] , [29] , [30] , [31] , [32] . Hepatocyte apoptosis and necrosis also induce the release of cellular miRNAs directly into the circulation, explaining the superior sensitivity of serum miRNA levels compared to ALT or AST levels in liver damage diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Serum MicroRNAs as Potential Biomarkers of Primary Biliary Cirrhosis

Pan

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

BackgroundCirculating microRNAs (miRNAs), which are extremely stable and protected from RNAse-mediated degradation in body fluids, have emerged as candidate biomarkers for many diseases. The present study aimed to identify a serum microRNA (miRNA) expression profile that could serve as a novel diagnostic biomarker for primary biliary cirrhosis (PBC).MethodsSerum miRNA expression was investigated using four cohorts comprising 380 participants (healthy controls and patients with PBC) recruited between August 2010 and June 2013. miRNA expression was initially analyzed by Illumina sequencing using serum samples pooled from 3 patients and 3 controls. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) was then used to evaluate the expression of selected miRNAs in a screening set (n = 40). A logistic regression model was then constructed using a training cohort (n = 192) and validated using another cohort (n = 142). The area under the receiver operating characteristic curve (AUC) was used to evaluate diagnostic accuracy.ResultsWe identified a miRNA panel (hsa-miR-122-5p, hsa-miR-141-3p, and hsa-miR-26b-5p) with a high diagnostic accuracy for PBC (AUC = 0.905, 95% confidence interval (CI) = 0.857 to 0.953; sensitivity = 80.5%, specificity = 88.3%). There was a significant difference between AUC values of the miRNA panel and those of alkaline phosphatase (ALP) (AUC = 0.537, difference between areas = 0.314, 95% CI = 0.195 to 0.434, P<0.001), and those of antinuclear antibody (ANA) (AUC = 0.739, difference between areas = 0.112, 95% CI = 0.012 to 0.213, P = 0.0282).ConclusionWe identified a serum microRNA panel with considerable clinical value in PBC diagnosis. The results indicate that the miRNA panel is a more sensitive and specific biomarker for PBC than ALP and ANA.

show abstract

“…Another review summarized the function of circulating miRNAs12, and a meta-analysis included 14 studies involving 1,848 cases with HCC and 1187 controls concluded that the miRNA panels can be biomarkers for HCC with AUC = 0.99 (96% sensitivity and 96% specificity)13. Many comprehensive reviews recommend to pay attentions to the role and function of miRNAs in disease diagnosis, prognosis and therapy141516171819202122. However, the differences in biological features of miRNAs between blood and tissues are still unclear, which limits the investigation on understanding clinical implications of miRNAs in different specimen.…”

mentioning

confidence: 99%

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Shen

Lin

Yuan

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Hepatocellular Carcinoma (HCC) is one of the most common malignant tumors with high incidence and mortality rate. Precision and effective biomarkers are therefore urgently needed for the early diagnosis and prognostic estimation. MicroRNAs (miRNAs) are important regulators which play functions in various cellular processes and biological activities. Accumulating evidence indicated that the abnormal expression of miRNAs are closely associated with HCC initiation and progression. Recently, many biomarker miRNAs for HCC have been identified from blood or tissues samples, however, the universality and specificity on clinicopathological features of them are less investigated. In this review, we comprehensively surveyed and compared the diagnostic, prognostic, and therapeutic roles of HCC biomarker miRNAs in blood and tissues based on the cancer hallmarks, etiological factors as well as ethnic groups, which will be helpful to the understanding of the pathogenesis of biomarker miRNAs in HCC development and further provide accurate clinical decisions for HCC diagnosis and treatment.

show abstract

Les microARN dans le cancer du foie

Cited by 10 publications

References 35 publications

A Pilot Study of Serum MicroRNAs Panel as Potential Biomarkers for Diagnosis of Nonalcoholic Fatty Liver Disease

A Pilot Study of Serum MicroRNAs Panel as Potential Biomarkers for Diagnosis of Nonalcoholic Fatty Liver Disease

Serum MicroRNAs as Potential Biomarkers of Primary Biliary Cirrhosis

Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison

Contact Info

Product

Resources

About